

Contents

List of Contributors	XVII
Preface	XXI
A Personal Foreword	XXIII

Part One Prodrug Design and Intellectual Property 1

1	Prodrug Strategies in Drug Design	3
	<i>Jarkko Rautio</i>	
1.1	Prodrug Concept	3
1.2	Basics of Prodrug Design	4
1.3	Rationale for Prodrug Design	5
1.3.1	Overcoming Formulation and Administration Problems	6
1.3.2	Overcoming Absorption Barriers	8
1.3.3	Overcoming Distribution Problems	9
1.3.4	Overcoming Metabolism and Excretion Problems	10
1.3.5	Overcoming Toxicity Problems	10
1.3.6	Life Cycle Management	13
1.4	History of Prodrug Design	14
1.5	Recently Marketed Prodrugs	17
1.5.1	Prodrug Prevalence	17
1.5.2	Recent Prodrug Approvals	17
1.6	Concluding Remarks	25
	References	26
2	The Molecular Design of Prodrugs by Functional Group	31
	<i>Victor R. Guarino</i>	
2.1	Introduction	31
2.2	The Prodrug Concept and Basics of Design	32
2.3	Common Functional Group Approaches in Prodrug Design	34

Prodrugs and Targeted Delivery: Towards Better ADME Properties. Edited by Jarkko Rautio
 Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
 ISBN: 978-3-527-32603-7

2.3.1	Aliphatic and Aromatic Alcohols	34
2.3.1.1	Phosphate Monoesters	35
2.3.1.2	Simple Acyl Esters	37
2.3.1.3	Amino Acid Esters	38
2.3.1.4	Other Ester-Based Approaches	39
2.3.2	Carboxylic Acids	40
2.3.2.1	Alkyl Esters	41
2.3.2.2	Aminoalkyl Esters	42
2.3.2.3	Spacer Groups to Alleviate Steric Hindrance	42
2.3.3	Imides, Amides, and Other NH Acids	43
2.3.3.1	Imide-Type NH Acids	44
2.3.3.2	Amide-Type NH Acids	44
2.3.3.3	Sulfonamide NH Acids	48
2.3.4	Phosphates, Phosphonates, and Phosphinates	49
2.3.4.1	Simple Alkyl and Aryl Esters	49
2.3.4.2	Acyloxyalkyl and Alkoxy-carbonyloxyalkyl Esters	50
2.3.4.3	Aryl Phospho(n/r)amidates and Phospho(n/r)diamides	51
2.3.4.4	HepDirect Technology	53
2.3.5	Amines and Benzamidines	53
2.3.5.1	N-Acyloxyalkoxycarbonyl Prodrugs	54
2.3.5.2	N-Mannich Bases	55
2.3.5.3	N-Acyloxyalkyl and N-Phosphoryloxyalkyl Prodrugs of Tertiary Amines	55
2.3.5.4	N-Hydroxy and Other Modifications for Benzamidines	56
2.4	Conclusions	56
	References	57
3	Intellectual Property Primer on Pharmaceutical Patents with a Special Emphasis on Prodrugs and Metabolites	61
	<i>Eyal H. Barash</i>	
3.1	Introduction	61
3.2	Patents and FDA Approval Process	61
3.3	Obtaining a Patent	65
3.3.1	Utility	66
3.3.2	Novelty	67
3.3.3	Nonobviousness	71
3.4	Conclusion	78
Part Two	Prodrugs Addressing ADMET Issues	79
4	Increasing Lipophilicity for Oral Drug Delivery	81
	<i>Majid Y. Moridani</i>	
4.1	Introduction	81
4.2	pK_a , Degree of Ionization, Partition Coefficient, and Distribution Coefficient	81

4.3	Prodrug Strategies to Enhance Lipid Solubility	85
4.4	Prodrug Examples for Antibiotics	87
4.4.1	Bacampicillin	87
4.4.2	Carindacillin	88
4.4.3	Cefditoren Pivoxil	89
4.4.4	Cefuroxime Axetil	90
4.4.5	Cefpodoxime Proxetil	91
4.5	Antiviral Related Prodrugs	92
4.5.1	Oseltamivir	92
4.5.2	Famciclovir	92
4.5.3	Adefovir Dipivoxil	93
4.5.4	Tenofovir Disoproxil	94
4.6	Cardiovascular Related Prodrugs	95
4.6.1	Enalapril	95
4.6.2	Fosinopril	96
4.6.3	Olmesartan Medoxomil	97
4.7	Lipophilic Prodrugs of Benzamidine Drugs	98
4.7.1	Ximelagatran	98
4.7.2	Dabigatran Etxilate	99
4.8	Miscellaneous Examples	100
4.8.1	Capecitabine	100
4.8.2	Mycophenolate Mofetil	101
4.8.3	Misoprostol	102
4.8.4	Additional Examples	102
4.9	Summary and Conclusion	104
	References	106
5	Modulating Solubility Through Prodrugs for Oral and IV Drug Delivery	111
	<i>Victor R. Guarino</i>	
5.1	Introduction	111
5.2	Basics of Solubility and Oral/IV Drug Delivery	112
5.2.1	Some Basic Fundamentals of Solubility	112
5.2.2	Some General Comments on IV Drug Delivery	114
5.2.3	Some General Comments on Oral Drug Delivery	116
5.3	Prodrug Applications for Enhanced Aqueous Solubility	117
5.3.1	Prodrug Concept	117
5.3.2	Examples of Prodrugs to Enhance Aqueous Solubility for IV Administration	118
5.3.2.1	Fosphenytoin	118
5.3.2.2	Fospropofol	119
5.3.2.3	Parecoxib	120
5.3.2.4	Irinotecan	120
5.3.3	Prodrugs to Enhance Aqueous Solubility for Oral Administration	121
5.3.3.1	Fosamprenavir	121

5.3.3.2	Valganciclovir	122
5.4	Challenges with Solubilizing Prodrugs of Insoluble Drugs	123
5.4.1	Challenges with Solubilizing Prodrug Strategies for IV Administration	123
5.4.2	Challenges with Solubilizing Prodrug Strategies for Oral Administration	124
5.5	Additional Applications of Prodrugs for Modulating Solubility	125
5.5.1	Alleviating pH-Dependent Oral Bioavailability of Weakly Basic Drugs	126
5.5.2	Aligning pH-Solubility and pH-Stability Relationships for IV Products	126
5.5.3	Modulating Solubility in Negative Direction	127
5.6	Parallel Exploration of Analogues and Prodrugs in Drug Discovery (Commentary)	128
5.7	Conclusions	129
	References	129
6	Prodrugs Designed to Target Transporters for Oral Drug Delivery	133
	<i>Mark S. Warren and Jarkko Rautio</i>	
6.1	Introduction	133
6.2	Serendipity: An Actively Transported Prodrug	133
6.3	Requirements for Actively Transported Prodrugs	135
6.4	Peptide Transporters: PEPT1 and PEPT2	135
6.5	Monocarboxylate Transporters	140
6.6	Bile Acid Transporters	143
6.7	Conclusions	147
	References	147
7	Topical and Transdermal Delivery Using Prodrugs: Mechanism of Enhancement	153
	<i>Kenneth Sloan, Scott C. Wasdo, and Susruta Majumdar</i>	
7.1	Introduction	153
7.2	Arrangement of Water in the Stratum Corneum	155
7.3	A New Model for Diffusion Through the Stratum Corneum: The Biphasic Solubility Model	156
7.4	Equations for Quantifying Effects of Solubility on Diffusion Through the Stratum Corneum	158
7.4.1	The Roberts–Sloan Equation When the Vehicle is Water	159
7.4.2	The Roberts–Sloan Equation When the Vehicle is a Lipid	160
7.4.3	The Series/Parallel Equation When the Vehicle is a Lipid	161
7.5	Design of Prodrugs for Topical and Transdermal Delivery Based on the Biphasic Solubility Model	162
7.5.1	5-Fluorouracil Prodrugs	164
7.5.1.1	N-Acyl 5-FU Prodrugs	165
7.5.1.2	N-Soft Alkyl 5-FU Prodrugs	166

7.5.2	Acetaminophen (APAP) Prodrugs	167
7.5.2.1	O-Acyl APAP Prodrugs	168
7.5.2.2	O-Soft Alkyl APAP Prodrugs	170
7.5.3	S-Soft Alkyl Prodrugs of 6-Mercaptopurine	170
7.5.3.1	Effect of Vehicles on Topical and Transdermal Delivery	171
7.6	Comparison of Human and Mouse Skin Experiments	172
7.7	Summary	174
	References	175
8	Ocular Delivery Using Prodrugs	181
	<i>Deep Kwatra, Ravi Vaishya, Ripal Gaudana, Jwala Jwala, and Ashim K. Mitra</i>	
8.1	Introduction	181
8.2	Criteria for an Ideal Ophthalmic Prodrug	181
8.3	Anatomy and Physiology of the Eye	182
8.3.1	Anterior Chamber	183
8.3.2	Posterior Chamber	183
8.4	Barriers to Ocular Drug Delivery	184
8.4.1	Tear Film	184
8.4.2	Corneal Epithelium	184
8.4.3	Aqueous Humor and BAB	184
8.4.4	Conjunctiva	184
8.4.5	Blood–Retinal Barrier	185
8.5	Influx and Efflux Transporters on the Eye	185
8.6	Transporter-Targeted Prodrug Approach	186
8.6.1	Acyclovir	186
8.6.2	Ganciclovir	188
8.6.3	Quinidine	188
8.7	Drug Disposition in Ocular Delivery	189
8.8	Effect of Physiochemical Factors on Drug Disposition in Eye	190
8.9	Prodrug Strategy to Improve Ocular Bioavailability (Nontransporter-Targeted Approach)	192
8.9.1	Epinephrine	192
8.9.2	Phenylephrine	192
8.9.3	Pilocarpine	193
8.9.4	Timolol	195
8.9.5	Prostaglandin F _{2α}	197
8.10	Recent Patents and Marketed Ocular Prodrugs	198
8.11	Novel Formulation Approaches for Sustained Delivery of Prodrugs	201
8.12	Conclusion	201
	References	202
9	Reducing Presystemic Drug Metabolism	207
	<i>Majid Y. Moridani</i>	
9.1	Introduction	207

9.2	Presystemic Metabolic Barriers	209
9.2.1	Esterases	209
9.2.2	Cytochrome P450 Enzymes	212
9.2.3	Phase II Drug Metabolizing Enzymes	214
9.2.4	Peptidases	215
9.2.5	Other Oxidative Metabolizing Enzymes	216
9.3	Prodrug Approaches to Reduce Presystemic Drug Metabolism	217
9.4	Targeting Colon	220
9.5	Targeting Lymphatic Route	221
9.6	Conclusion	225
	References	226

10 Enzyme-Activated Prodrug Strategies for Site-Selective Drug Delivery 231

Krista Laine and Kristiina Huttunen

10.1	Introduction	231
10.2	General Requirements for Enzyme-Activated Targeted Prodrug Strategy	232
10.3	Examples of Targeted Prodrug Strategies	232
10.3.1	Tumor-Selective Prodrugs	232
10.3.1.1	Prodrugs Activated by Hypoxia-Associated Reductive Enzymes	233
10.3.1.2	Prodrugs Activated by Glutathione S-Transferase	236
10.3.1.3	Prodrugs Activated by Thymidine Phosphorylase	237
10.3.2	Organ-Selective Prodrugs	239
10.3.2.1	Liver-Targeted Prodrugs	239
10.3.2.2	Kidney-Targeted Prodrugs	242
10.3.2.3	Colon-Targeted Prodrugs	243
10.3.3	Virus-Selective Prodrugs	244
10.4	Summary	245
	References	246

11 Prodrug Approaches for Central Nervous System Delivery 253

Quentin R. Smith and Paul R. Lockman

11.1	Blood–Brain Barrier in CNS Drug Development	253
11.2	Prodrug Strategies	255
11.3	Prodrug Strategies Based Upon BBB Nutrient Transporters	257
11.4	Prodrug Strategies Based Upon BBB Receptors	263
11.5	CNS Prodrug Summary	264
	References	266

12 Directed Enzyme Prodrug Therapies 271

Dan Niculescu-Duvaz, Gabriel Negoita-Giras, Ion Niculescu-Duvaz, Douglas Hedley, and Caroline J. Springer

12.1	Introduction	271
12.2	Theoretical Background of DEPT	271

12.2.1	ADEPT and Other Enzyme–Conjugates Approaches	272
12.2.2	LIDEPT	273
12.2.3	GDEPT and Other Gene Delivery Approaches	273
12.2.4	BDEPT	275
12.3	Comparison of ADEPT and GDEPT	275
12.4	Enzymes in ADEPT and GDEPT	278
12.5	Design of Prodrugs	282
12.5.1	Mechanisms of Prodrug Activation	282
12.5.1.1	Electronic Switch	282
12.5.1.2	Cell Exclusion	285
12.5.1.3	Blockage of the Pharmacophore	285
12.5.1.4	Conversion to Substrate for Endogenous Enzymes	287
12.5.1.5	Formation of a Reactive Moiety	287
12.5.1.6	Formation of a Second Interactive Group	288
12.5.2	Enzymatic Reactions Activating the Prodrug. The Trigger	288
12.5.2.1	Reactions Catalyzed by Hydrolases: Hydrolytic Cleavage	289
12.5.2.2	Activation by Nucleotide Phosphorylation	290
12.5.2.3	Activation by Reductases	290
12.5.2.4	Activation by Oxidases	291
12.5.2.5	(Deoxy)Ribosyl Transfer	291
12.5.3	The Linker. Self-Immolative Prodrugs	292
12.5.3.1	Self-Immolative Prodrugs Fragmenting by Elimination	293
12.5.3.2	Linker–Drug Connection	293
12.5.3.3	Self-Immolative Prodrugs Fragmenting Following Cyclization	296
12.6	Strategies Used for the Improvement of DEPT Systems	296
12.6.1	Improvement of the Prodrug	296
12.6.1.1	Cytotoxicity Differential	297
12.6.1.2	Stability of Prodrugs	298
12.6.1.3	Cytotoxicity and Mechanism of Action of the Released Drug	299
12.6.1.4	Stability of the Released Drug	299
12.6.1.5	Resistance (Prodrug Related)	300
12.6.1.6	Kinetics of Activation	300
12.6.1.7	Physicochemical Properties	302
12.6.1.8	Pharmacokinetics	303
12.6.1.9	Specificity of Enzyme Activation	304
12.6.2	Improving the Enzymes	304
12.6.3	The Multigene Approach	305
12.6.4	Enhancing the Immune Response	307
12.7	Biological Data for ADEPT and GDEPT	307
12.7.1	Bacteria	308
12.7.2	Viruses	308
12.7.3	Adenoviral Vectors	308
12.7.4	Pox Viral Vectors	309
12.7.5	Adeno-Associated Viral Vectors	309

12.7.6	Retroviral Vectors	309
12.7.7	Lentiviral Vectors	310
12.7.8	Measles Viral Vectors	310
12.7.9	Herpes Simplex Viral Vectors	311
12.7.10	Neural Stem Cells/Progenitor Cells	311
12.7.11	Liposomes	311
12.7.12	ADEPT Vectors	312
12.7.13	Vectors for Prodrugs	312
12.7.14	Clinical Studies	316
12.8	Conclusions	316
	References	318

Part Three Codrugs and Soft Drugs 345

13	Improving the Use of Drug Combinations Through the Codrug Approach	347
	<i>Peter A. Crooks, Harpreet K. Dhooper, and Ujjwal Chakraborty</i>	
13.1	Codrugs and Codrug Strategy	347
13.2	Ideal Codrug Characteristics	348
13.3	Examples of Marketed Codrugs	349
13.4	Topical Codrug Therapy for the Treatment of Ophthalmic Diseases	351
13.4.1	Codrugs for the Treatment of Diabetic Retinopathy	351
13.4.2	Codrugs Containing Corticosteroids for Proliferative Vitreoretinopathy	353
13.4.3	Codrugs Containing Nonsteroidal Anti-Inflammatory Agents for Treatment of Proliferative Vitreoretinopathy	355
13.4.4	Codrugs Containing Ethacrynic Acid for Treatment of Elevated Intraocular Pressure	356
13.5	Codrugs for Transdermal Delivery	357
13.5.1	Codrugs for the Treatment of Alcohol Abuse and Tobacco Dependence	357
13.5.2	Duplex Codrugs of Naltrexone for Transdermal Delivery	362
13.5.3	Codrugs Containing α -Tocopherol for Skin Hydration	362
13.6	Codrugs of L-DOPA for the Treatment of Parkinson's Disease	363
13.6.1	L-DOPA Codrugs that Incorporate Inhibitors of L-DOPA Metabolism	363
13.6.2	L-DOPA-Antioxidant Codrugs	364
13.7	Analgesic Codrugs Containing Nonsteroidal Anti-Inflammatory Agents	367
13.7.1	Flurbiprofen-Histamine H ₂ Antagonist Codrugs	367
13.7.2	NSAID-Acetaminophen Codrugs	368
13.7.3	Naproxen-Propyphenazone Codrugs	370
13.7.4	Flurbiprofen-Amino Acid Codrugs	371
13.7.5	NSAID-Chlorzoxazone Codrugs	372

13.7.6	Acetaminophen–Chlorzoxazone Codrug	373
13.8	Analgesic Codrugs of Opioids and Cannabinoids	373
13.9	Codrugs Containing Anti-HIV Drugs	375
13.9.1	AZT–Retinoic Acid Codrug	377
	References	378
14	Soft Drugs	385
	<i>Paul W. Erhardt and Michael D. Reese</i>	
14.1	Introduction	385
14.1.1	Definition	385
14.1.2	Prototypical Agent	386
14.1.2.1	Backdrop	386
14.1.2.2	Clinical Challenge	386
14.1.2.3	Pharmacological Target	388
14.1.2.4	Pharmacology, Human Pharmacokinetic Profile, and Clinical Deployment	389
14.2	Indications	390
14.2.1	A Huge Potential	391
14.2.2	“To Market, To Market”	392
14.3	Design Considerations	396
14.3.1	General Requirements	396
14.3.2	Enzymatic Aspects	397
14.3.3	Chemical Structural Aspects	397
14.4	Case Study: The Discovery of Esmolol	400
14.4.1	Internal Esters	400
14.4.2	External Esters	402
14.4.3	“Square Pegs and Round Holes”	402
14.4.4	Surrogate Scaffolds for Testing Purposes and a “Glimmer of Hope”	403
14.4.5	A “Goldilocks” Compound Called Esmolol	404
14.4.6	“Esmolol Stat”	406
14.4.7	Case Study Summary and Some Take-Home Lessons for Today	407
14.4.7.1	Compound Libraries	407
14.4.7.2	Biological Testing	408
14.4.7.3	SAR	408
14.5	Summary	408
	References	409
Part Four	Preclinical and Clinical Consideration for Prodrugs	415
15	Pharmacokinetic and Biopharmaceutical Considerations in Prodrug Discovery and Development	417
	<i>John P. O'Donnell</i>	
15.1	Introduction	417

15.2	Understanding Pharmacokinetic/Pharmacodynamic Relationships	417
15.3	Pharmacokinetics	418
15.4	Tools for the Prodrug Scientist	421
15.4.1	Bioanalytical Assay Development	421
15.4.2	Use of Radiolabel	422
15.5	Enzymes Involved with Prodrug Conversion	423
15.5.1	Carboxylesterases	423
15.5.2	Alkaline Phosphatase	426
15.5.3	Cytochrome P450	428
15.6	Use of the Caco-2 System for Permeability and Active Transport Evaluation	428
15.7	XP13512: Improving PK Performance by Targeting Active Transport	432
15.8	Prodrug Absorption: Transport/Metabolic Conversion Interplay	434
15.8.1	Pivampicillin	434
15.8.2	Valacyclovir	436
15.9	Preabsorptive Degradation	438
15.9.1	Cephalosporin Prodrugs	438
15.9.2	Sulopenem Prodrugs PF-00398899, PF-03709270, and PF-04064900	439
15.10	Biopharmaceutical-Based PK Modeling for Prodrug Design	440
15.11	Conclusions	447
	References	447
16	The Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs	453
	<i>Jane P.F. Bai, Mike Pacanowski, Atiqur Rahman, and Lawrence L. Lesko</i>	
16.1	Introduction	453
16.2	Clopidogrel and CYP2C19	454
16.2.1	Summary	457
16.3	Codeine and CYP2D6	457
16.3.1	Summary	460
16.4	Tamoxifen and CYP2D6	460
16.4.1	Summary	463
16.5	Fluorouracil Prodrugs and Carboxylesterase	464
16.5.1	Capecitabine and Carboxylesterase	465
16.5.1.1	Summary	467
16.5.2	Tegafur and CYP2A6	467
16.5.2.1	Summary	468
16.6	Irinotecan and Carboxylesterase 2	468
16.6.1	Summary	469
16.7	Others	470

16.7.1	ACE Inhibitors and CES	470
16.7.2	Cyclophosphamide and CYP2B6/CYP2C19	470
16.7.2.1	Summary	471
16.8	Drug Development Implication	471
16.9	Conclusions	473
	References	473
	Index	483